Showing results (101-110 of 253) with videos related to
Sort By:
Pageof 26
British Journal of Haematology|January 4, 2020
Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapseVittorio Montefusco, Alessandro Corso, Monica Galli, et al.Haematologica|November 21, 2007
Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myelomaGösta Gahrton, Simona Iacobelli, Giuseppe Bandini, et al.Blood Advances|February 15, 2024
Monocytes in leukapheresis products affect the outcome of CD19-targeted CAR T-cell therapy in patients with lymphomaCristiana Carniti, Nicole M Caldarelli, Luca Agnelli, et al.Experimental Hematology|June 3, 2009
Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myelomaNicolaus Kröger, Anita Badbaran, Michael Lioznov, et al.Transplantation and Cellular Therapy|April 10, 2021
Multicenter Phase II Study on Haploidentical Bone Marrow Transplantation Using a Reduced-Intensity Conditioning Regimen and Posttransplantation Cyclophosphamide in Patients with Poor-Prognosis LymphomasLuca Castagna, Anna Dodero, Francesca Patriarca, et al.Cancer|May 26, 2017
Next-generation sequencing of a family with a high penetrance of monoclonal gammopathies for the identification of candidate risk allelesNiccolo Bolli, Matteo Barcella, Erika Salvi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2011
Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-upBo Björkstrand, Simona Iacobelli, Ute Hegenbart, et al.Blood Advances|December 19, 2023
A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204)Tycel J Phillips, Abraham Avigdor, Ronit Gurion, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 10, 2017
Allogeneic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning RegimenAnna Dodero, Francesca Patriarca, Giuseppe Milone, et al.Blood Cancer Journal|July 19, 2024
Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myelomaBachisio Ziccheddu, Claudia Giannotta, Mattia D'Agostino, et al.Pageof 26